Research brief · Metabolic
Semaglutide
Reference GLP-1 agonist with a ~7-day half-life used in metabolic, incretin and appetite-pathway research models.
Class
GLP-1 receptor agonist
Half-life
~165 h (7 days)
Studied in
Glycemic regulation, appetite signaling, metabolic studies.
What it is
Semaglutide is a long-acting GLP-1 receptor agonist derived from the native human GLP-1 sequence with structural modifications that confer resistance to DPP-4 degradation and high-affinity albumin binding. In laboratory research it is widely used as a reference compound for incretin signaling, β-cell function assays and CNS appetite circuit models.
Mechanism studied
Selective agonism of the GLP-1 receptor modulating insulin secretion and gastric emptying.
Research notes
- Frequently paired with cagrilintide in dual incretin/amylin research protocols.
- Published rodent and in-vitro work focuses on β-cell preservation and hypothalamic POMC signaling.
- Albumin binding extends systemic exposure and supports once-weekly dosing models.
Before sourcing any material
- Confirm a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity).
- Check the stated peptide content per vial, not just the gross vial mass.
- Plan reconstitution volumes first so the vial size matches your protocol.
- Verify what is lawful in your jurisdiction — these are in-vitro research reagents, not medicines.
